The authors initially identified CCL3 as a factor suppressing tumor growth in vivo; however, in contrast to CCL7, their screening approach under anti-PD-1 therapy suggests that it may also play a role in driving immune cell exclusion from the tumor site. Here, CCL3 is linked to neoplasm.